title: Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation.
abstract: BACKGROUND
  Physicians managing patients with nonvalvular atrial fibrillation must consider the risks, benefits, and costs of treatments designed to restore and maintain sinus rhythm compared with those of rate control with antithrombotic prophylaxis.
  
  
  OBJECTIVE
  To compare the cost-effectiveness of cardioversion, with or without antiarrhythmic agents, with that of rate control plus warfarin or aspirin.
  
  
  METHODS
  A Markov decision-analytic model was designed to simulate long-term health and economic outcomes.
  
  
  METHODS
  Published literature and hospital accounting information.
  
  
  METHODS
  Hypothetical cohort of 70-year-old patients with different baseline risks for stroke.
  
  
  METHODS
  3 months.
  
  
  CONCLUSIONS
  Societal.
  
  
  METHODS
  Therapeutic strategies using different combinations of cardioversion alone, cardioversion plus amiodarone or quinidine therapy, and rate control with antithrombotic treatment.
  
  
  METHODS
  Expected costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness.
  
  
  RESULTS
  Strategies involving cardioversion alone were more effective and less costly than those not involving this option. For patients at high risk for ischemic stroke (5.3% per year), cardioversion alone followed by repeated cardioversion plus amiodarone therapy on relapse was most cost-effective ($9300 per QALY) compared with cardioversion alone followed by warfarin therapy on relapse. This strategy was also preferred for the moderate-risk cohort (3.6% per year), but the benefit was more expensive ($18,900 per QALY). In the lowest-risk cohort (1.6% per year), cardioversion alone followed by aspirin therapy on relapse was optimal.
  
  
  RESULTS
  The choice of optimal strategy and incremental cost-effectiveness was substantially influenced by the baseline risk for stroke, rate of stroke in sinus rhythm, efficacy of warfarin, and costs and utilities for long-term warfarin and amiodarone therapy.
  
  
  CONCLUSIONS
  Cardioversion alone should be the initial management strategy for persistent nonvalvular atrial fibrillation. On relapse of arrhythmia, repeated cardioversion plus low-dose amiodarone is cost-effective for patients at moderate to high risk for ischemic stroke.
authors.affiliation: Cardiology Division, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 03756-0001, USA.
authors.forename: E
authors.initials: E
authors.lastname: Catherwood
authors.forename: W D
authors.initials: WD
authors.lastname: Fitzpatrick
authors.forename: M L
authors.initials: ML
authors.lastname: Greenberg
authors.forename: P T
authors.initials: PT
authors.lastname: Holzberger
authors.forename: D J
authors.initials: DJ
authors.lastname: Malenka
authors.forename: B R
authors.initials: BR
authors.lastname: Gerling
authors.forename: J D
authors.initials: JD
authors.lastname: Birkmeyer
mesh_terms: D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000628:therapy*; D002561:Cerebrovascular Disorders / Q000209:etiology; D003131:Combined Modality Therapy; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D004554:Electric Countershock / Q000191:economics*; D005260:Female; D006801:Humans; D008297:Male; D008390:Markov Chains; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D012008:Recurrence; D012307:Risk Factors; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D001241:Aspirin